New analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy

New analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy

Apr 02, 2016
Source URL: https://qa1.novartis.us/us-en/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or-hospitalization-heart-failure-consistently-benefitting-patients-reduced-ejection-fraction-hfref-regardless-prior-heart-failure-hospital-admissions-or-background-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or-hospitalization-heart-failure-consistently-benefitting-patients-reduced-ejection-fraction-hfref-regardless-prior-heart-failure-hospital-admissions-or-background-0